Oral Cladribine B-cell Study - Trial NCT06415864
Access comprehensive clinical trial information for NCT06415864 through Pure Global AI's free database. This phase not specified trial is sponsored by Queen Mary University of London and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Queen Mary University of London
Timeline & Enrollment
N/A
Jul 01, 2019
Jan 31, 2024
Primary Outcome
To study B cells subsets changes
Summary
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells
 and Tregs
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06415864
Non-Device Trial